Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02205476 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Extension Study To Enroll Subjects Who Were Enrolled In B5301001 Study
A Phase 2 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT02205476 is a Phase 2 study that was terminated before completion, run by Pfizer. The registered enrollment target is 10 participants.
The verdict
NCT02205476, a Phase 2 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
Study is a multicenter, two-part, open-label phase II study in adults, evaluating the safety and long-term efficacy of PF-06473871 one year after surgical revision and treatment with PF-06473871.
Interventions
- DRUG PF-06473871
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2014-12 |
| Est. Completion | 2015-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02205476
The ClinicalTrials.gov registry entry for NCT02205476 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PF-06473871 is the first listed.
NCT02205476 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02205476 about?
NCT02205476 is a clinical study titled "A Phase 2 Extension Study To Enroll Subjects Who Were Enrolled In B5301001 Study". Study is a multicenter, two-part, open-label phase II study in adults, evaluating the safety and long-term efficacy of PF-06473871 one year after surgical revision and treatment with PF-06473871.
What is the current status of trial NCT02205476?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2014-12. Estimated completion is 2015-01.
What interventions are being tested in trial NCT02205476?
The interventions under investigation include: PF-06473871 (DRUG).
Who is sponsoring clinical trial NCT02205476?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.